Bioregnum channel feed – Endpoints News

Bioregnum channel feed

Pfizer preps a laundry list of drug price hikes for the New Year — let the political fireworks begin

7 years ago

Bound to the hip with Trump, ex-Celgene chief Bob Hugin gets whipped in New Jersey Senate race

7 years ago

Fight! Trump kicks off a war of words with the drug lobby, proposing to peg Medicare prices to overseas rates

7 years ago

Sarepta shares yo-yo in the red on another glimpse of stellar results for Duchenne MD gene therapy — what gives?

7 years ago

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

7 years ago

Juno will pay $24M to settle the JCAR015 scandal — but don’t expect that to change industry attitudes on reporting snafus

7 years ago

Vertex’s fight club rule: Block new treatments to cystic fibrosis patients until Orkambi is reimbursed properly

7 years ago

GSK chief Emma Walmsley rounds out her top team with CFO pick — but performance lags

7 years ago

This is it? GSK rolls out a buzzy new R&D plan long on aspirations and short on performance goals

7 years ago

Federal judges ban Allergan’s sovereign immunity scheme in a slapdown that will bolster inter partes review for years to come

7 years ago

Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up

7 years ago

Step right up: A biotech may soon sell an experimental med to dying ALS patients under 'Right to Try'

7 years ago

Another cheap, old drug is being freshened up for brand pricing in the US — and shares soar, briefly

7 years ago

Novartis sacrifices its top attorney in an attempt to quell clamor over $1.2M in Cohen payments — while ex-CEO Jimenez struggles to explain

7 years ago

Trump is kicking the can down the road today, avoiding any tough prescriptions on drug pricing

7 years ago

Novartis now says that it paid Trump's attorney $1.2M — and then throws ex-CEO Joe Jimenez under the bus

8 years ago

As a prominent analyst predicts (eventual) drug price controls, biopharma braces for a blow while Trump balls his fist

8 years ago

Does the FDA’s ‘breakthrough’ drug program need to be reformed? Harvard skeptics say yes

8 years ago

The 2-trial hurdle for drug approvals is steadily losing ground. Are we devaluing the industry's R&D gold standard?

8 years ago

Lies, damn lies and statistics: A Stanford wiz says P<0.05 offers deceptive evidence of biopharmas' drug claims

8 years ago

GSK’s Luke Miels applies budget shock therapy to shake up the pharma group, refocus on blockbusters

8 years ago

The Martin Shkreli saga ends today, but the issue he raised on drug pricing seems immortal

8 years ago

Is tech money bad for business? Silicon Valley cash makes some biopharma VCs bristle, others cheer

8 years ago

The FDA raises hopes for Alzheimer's drugs with a new set of draft rules. But are they going too far?

8 years ago

First page Previous page 9 10 111213 14 15 Next page Last page